Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/179337
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Arribas, Lorena | - |
dc.contributor.author | Plana, Maria | - |
dc.contributor.author | Taberna, Miren | - |
dc.contributor.author | Sospedra, Maria | - |
dc.contributor.author | Vilariño, Noelia | - |
dc.contributor.author | Oliva, Marc | - |
dc.contributor.author | Pallarés, Natàlia | - |
dc.contributor.author | González Tampán, Ana Regina | - |
dc.contributor.author | Rio, Luis Miguel del | - |
dc.contributor.author | Mesia, Ricard | - |
dc.contributor.author | Baracos, Vickie | - |
dc.date.accessioned | 2021-07-22T10:18:25Z | - |
dc.date.available | 2021-07-22T10:18:25Z | - |
dc.date.issued | 2021-06-25 | - |
dc.identifier.issn | 2234-943X | - |
dc.identifier.uri | http://hdl.handle.net/2445/179337 | - |
dc.description.abstract | Background Reduced muscle mass has been associated with increased treatment complications in several tumor types. We evaluated the impact of skeletal muscle index (SMI) on prognosis and immune-related adverse events (IrAEs) in a cohort of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoints inhibitors (ICI). Methods A single-institutional, retrospective study was performed including 61 consecutive patients of R/M HNSCC diagnosed between July 2015 and December 2018. SMI was quantified using a CT scan at L3 to evaluate body composition. Median baseline SMI was used to dichotomize patients in low and high SMI. Kaplan-Meier estimations were used to detect overall survival (OS) and progression-free survival (PFS). Toxicity was recorded using Common Terminology Criteria for Adverse Event v4.3. Results Patients were 52 men (85.2%) with mean of age 57.7 years (SD 9.62), mainly oral cavity (n = 21; 34.4%). Low SMI was an independent factor for OS in the univariate (HR, 2.06; 95% CI, 1.14-3.73, p = 0.017) and multivariate Cox analyses (HR, 2.99; 95% CI, 1.29-6.94; p = 0.011). PFS was also reduced in patients with low SMI (PFS HR, 1.84; 95% CI, 1.08-3.12; p = 0.025). IrAEs occurred in 29 (47.5%) patients. There was no association between low SMI and IrAEs at any grade (OR, 0.56; 95% CI, 0.20-1.54; p = 0.261). However, grades 3 to 4 IrAEs were developed in seven patients of whom three had low SMI. Conclusions Low SMI before ICI treatment in R/M HNSCC patients had a negative impact on OS and PFS. Further prospective research is needed to confirm the role of body composition as a predictive biomarker in ICI treatment. | - |
dc.format.extent | 8 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media SA | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fonc.2021.699668 | - |
dc.relation.ispartof | Frontiers in Oncology, 2021, vol. 11, num. 699668 | - |
dc.relation.uri | https://doi.org/10.3389/fonc.2021.699668 | - |
dc.rights | cc by (c) Arribas, Lorena et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Pronòstic mèdic | - |
dc.subject.classification | Marcadors bioquímics | - |
dc.subject.classification | Càncer de coll | - |
dc.subject.classification | Càncer de cap | - |
dc.subject.other | Prognosis | - |
dc.subject.other | Biochemical markers | - |
dc.subject.other | Neck cancer | - |
dc.subject.other | Head cancer | - |
dc.title | Predictive Value of Skeletal Muscle Mass in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients Treated With Immune Checkpoint Inhibitors | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-07-22T10:01:47Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 34249760 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
fonc-11-699668.pdf | 916.5 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License